Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

ASCO 2011: broadening the horizons of cancer research.

Crane K.

J Natl Cancer Inst. 2011 Jul 6;103(13):999-1001. doi: 10.1093/jnci/djr251. Epub 2011 Jun 21. No abstract available.

PMID:
21693729
2.

Researchers optimistic about sea change in cancer treatment.

Stephenson J.

JAMA. 2001 Jun 13;285(22):2841-2. No abstract available.

PMID:
11401587
3.

Trial offers early test case for personalized medicine.

Garber K.

J Natl Cancer Inst. 2009 Feb 4;101(3):136-8. doi: 10.1093/jnci/djn506. Epub 2009 Jan 27. No abstract available.

PMID:
19176464
4.

American Association of Cancer Research Showcases Immunotherapy Advances.

Brower V.

J Natl Cancer Inst. 2015 Aug 4;107(8). pii: djv231. doi: 10.1093/jnci/djv231. Print 2015 Aug. No abstract available.

5.

Trastuzumab trials steal show at ASCO meeting.

Tuma RS.

J Natl Cancer Inst. 2005 Jun 15;97(12):870-1. No abstract available.

PMID:
15956644
6.

Beyond Herceptin and Gleevec.

Fischer OM, Streit S, Hart S, Ullrich A.

Curr Opin Chem Biol. 2003 Aug;7(4):490-5. Review.

PMID:
12941424
7.

Targeted cancer therapies attempt to hit the bull's-eye.

Miller M.

J Natl Cancer Inst. 2000 Dec 6;92(23):1878-9. No abstract available.

PMID:
11106678
8.

Experts debate value of HER2 testing methods.

Nelson NJ.

J Natl Cancer Inst. 2000 Feb 16;92(4):292-4. No abstract available.

PMID:
10675369
9.

HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.

Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, Chilosi M, Bonetti F.

Am J Clin Pathol. 2008 Jun;129(6):907-11. doi: 10.1309/MD79CDXN1D01E862.

PMID:
18480007
10.

Targeted therapy in cancer and transgenic animal model.

Inui A.

Cancer Invest. 2003;21(5):819-20. No abstract available.

PMID:
14628441
11.

[National Conference of Medical Oncology. New trends in cancer therapy. Genova, October 29, 2000].

Longo F, Mansueto G.

Tumori. 2000 Nov-Dec;86(6):A5-12. Italian. No abstract available.

PMID:
11271676
12.

Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG.

J Clin Oncol. 2012 Jan 1;30(1):88-109. doi: 10.1200/JCO.2011.40.1919. Epub 2011 Dec 5.

PMID:
22147736
13.

Development trends for monoclonal antibody cancer therapeutics.

Reichert JM, Valge-Archer VE.

Nat Rev Drug Discov. 2007 May;6(5):349-56. Review.

PMID:
17431406
14.

Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA.

Burstein HJ.

Expert Rev Anticancer Ther. 2005 Aug;5(4):581-3. No abstract available.

PMID:
16111459
15.

[Molecular targeted therapy].

Stenner-Liewen F, Zippelius A, Pestalozzi BC, Knuth A.

Chirurg. 2006 Dec;77(12):1118-25. Review. German.

PMID:
17109101
16.

American Association for Cancer Research 100th Annual Meeting.

Carlson RH.

Lancet Oncol. 2009 Jun;10(6):546. No abstract available.

PMID:
19504663
17.

The distinctive nature of HER2-positive breast cancers.

Burstein HJ.

N Engl J Med. 2005 Oct 20;353(16):1652-4. No abstract available.

18.

ASCO 2012: a good year for HER2 therapy.

Sledge GW Jr.

Clin Breast Cancer. 2012 Aug;12(4):231. doi: 10.1016/j.clbc.2012.06.001. No abstract available.

PMID:
22858362
19.

Human epidermal growth factor receptor 2 testing recommendation.

Raji A, Lurie RH.

Arch Pathol Lab Med. 2007 Sep;131(9):1330-1; author reply 1331-3. No abstract available.

PMID:
17824785
20.

Beyond chemotherapy--demystifying the new 'targeted' cancer treatments.

Dear R, Wilcken N, Shannon J.

Aust Fam Physician. 2008 Jan-Feb;37(1-2):45-9. Review.

PMID:
18239753

Supplemental Content

Support Center